Actavis U.S., the United States manufacturing and marketing division of the international generic pharmaceutical company Actavis Group, announced that it has received approval from the U.S. Food & Drug Administration to market Trimipramine Maleate Capsules. Distribution of the product will commence immediately.
Trimipramine Maleate Capsules, the generic equivalent of Odyssey Pharmaceutical's Surmontil® Capsules, will be available in 25mg, 50mg and 100mg strengths. Trimipramine Maleate is indicated for depression, anxiety, insomnia, chronic pain, and alcohol and opioid withdrawal.